TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07743463: A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Sponsor: Ascletis Pharma (China) Co., Limited · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 3003 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07743463 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07743463 Rescue Dossier →